Zenith Drugs (NSE:ZENITHDRUG) Long-Term Debt: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
35 GF Score
Price ₹47.80
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Long-Term Debt?

Zenith Drugs NSE:ZENITHDRUG +4.03% 35 Long-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 8 warning signs investors should review.

Zenith Drugs's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹0 Mil.

Zenith Drugs's quarterly Long-Term Debt declined from Mar. 2025 (₹128 Mil) to Sep. 2025 (₹0 Mil) but then stayed the same from Sep. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Zenith Drugs's annual Long-Term Debt increased from Mar. 2024 (₹79 Mil) to Mar. 2025 (₹128 Mil) but then declined from Mar. 2025 (₹128 Mil) to Mar. 2026 (₹0 Mil).

Zenith Drugs  (NSE:ZENITHDRUG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Zenith Drugs Long-Term Debt Related Terms

Zenith Drugs Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Long-Term Debt Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial 0.00 83.63 78.53 127.96 0.00

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only 78.53 0.00 127.96 0.00 0.00
NSE:ZENITHDRUG
35GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Long-Term Debt of ₹0 Mil as of Mar. 2026.
Is Zenith Drugs' Long-Term Debt too high?
Zenith Drugs' current Long-Term Debt is ₹0 Mil. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Long-Term Debt compare to ZTS?
Zenith Drugs' Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Zenith Drugs's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Long-Term Debt of ₹0 Mil. The current Long-Term Debt is ₹0 Mil. Zenith Drugs' overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Long-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score

Get the complete analysis for NSE:ZENITHDRUG

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹47.80
Price